Home Patent Forecast® Sectors Log In   Sign Up   Support   Contact  
Enjoy your FREE PREVIEW which shows only 2018 data and 25 documents. For full access, subscribe at any time.         Subscribe


GW Pharmaceuticals, Plc

GW Pharmaceuticals (GW) is a British biopharmaceuticals company that is the largest assignee in the sector. GW is focused on developing and marketing therapeutics based on plant-derived cannabinoid compounds. GW saw early success with Epidolex, the first cannabis plant-derived medicine approved by the FDA, which is used to treat patients with rare epilepsy diseases (Dravet syndrome and Lennox-Gastaut syndrome). GW also has developed Sativex, which is used to treat patients with multiple sclerosis. GW is primarily focused on neurological conditions, including conditions with both orphan and non-orphan status.

News and Insights

GW Pharmaceuticals, Plc Owned Patent Documents in this Patent Forecast
Loading Documents...